Concepedia

Yoshiaki Okuma

YO

Statistics

Publications

4

Citations

287

H-Index

4

Active since

2003

Affiliations

University of Toyama(Current)

National Center for Global Health and Medicine

Tokyo Women's Medical University

Kagoshima City Hospital

National Center For Child Health and Development

Yoshiaki Okuma is an author at University of Toyama specializing in clinical immunology, immunology, and ischemic heart disease.

Publications per year

2003–2019

4

Publications

4

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

Hiroyuki Suzuki, Masaru Terai, Shigeto Fuse et al. · The Lancet · 2019 · 208 citations

Medicine, Cardiology, Immunology +11

Melatonin binding sites in estrogen receptor‐positive cells derived from human endometrial cancer

Yoichi Kobayashi, Masanori Itoh, Haruhiro Kondo et al. · Journal of Pineal Research · 2003 · 34 citations · Full text

Life Sciences, Endocrinology, Pharmacology +14

Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease　– A Multicenter Retrospective Study –

Yoshiaki Okuma, Kenji Suda, Hideyuki Nakaoka et al. · Circulation Journal · 2016 · 32 citations · Full text

Life Sciences, Cardiology, Immunology +14

307. EFFICACY OF PRIMARY TREATMENT WITH IMMUNOGLOBULIN PLUS CYCLOSPORINE FOR PREVENTION OF CORONARY ARTERY ABNORMALITIES IN KAWASAKI DISEASE PATIENTS PREDICTED TO BE AT INCREASED RISK OF IVIG NON- RESPONSE (KAICA STUDY): A CONTROLLED, PHASE 3, RANDOMISED, OPEN-LABEL, BLINDED-ENDPOINTS TRIAL

Hiromichi Hamada, Hiroyuki Suzuki, Yoshihiro Onouchi et al. · Lara D. Veeken · 2019 · 13 citations · Full text

Medicine, Immunology, Pharmacology +11

1–4 of 4